NUVL - Nuvalent, Inc.
About Nuvalent, Inc. (https://www.nuvalent.com)
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| James R. Porter | Chief Executive Officer, President & Director | 1976 | $1,143,133 USD |
| Christopher D. Turner | Chief Medical Officer | 1969 | $822,475 USD |
| Alex Balcom | Chief Financial Officer & Treasurer | 1984 | $753,791 USD |
| Darlene Noci | Chief Development Officer | 1978 | $741,317 USD |
| Deborah Ann Miller | Chief Legal Officer & Secretary | 1976 | $740,701 USD |
| Benjamin Lane | Chief Technical Operations Officer | – | – |
| Chelcie Lister | Senior Director of Investor Relations & Corporate Communications | – | – |
| Henry Pelish | Chief Scientific Officer | 1973 | – |
| John Soglia | Senior Vice President of Translational Development | – | – |
| Joshua Horan | Senior Vice President of Chemistry | – | – |
| Matthew Metivier | Senior Vice President of Human Resources | – | – |